Entero Healthcare Solutions Limited

ENTERO

Sector: HealthcareSub-sector: Pharmaceutical and MedTech Distribution
Qtr Score Rank 47 / 57 (Top 19 percentile)Growth Score Rank 7 / 51 (Top 88 percentile)

Quarterly Score

↔ Trend: Stable
Sentiment stable - Recent avg: 8.03, Historical avg: 8.17

Showing the latest 12 quarterly points (newest to oldest).

Score context (latest 12 quarters)

Q3 FY2024
7.8

Management targets 20% organic revenue growth (2x IPM) and aims to reach 5%+ EBITDA margins and 20%+ ROCE within a 2-3 year horizon through scale, private label expansion, and operating leverage.

Rationale

  • Revenue growth of 20% YoY for Q3 FY24 (₹993 Cr) and 9M FY24 (₹2,888 Cr) significantly outpaced the Indian Pharmaceutical Market (IPM) growth rate of 9%.
  • Material margin expansion with 9M FY24 EBITDA increasing 90% YoY and margins expanding 107 bps to 2.9%, driven by an 80 bps improvement in gross margins (9.0%) through procurement efficiencies and mix shift.
Q4 FY2024
8.7

Strongly bullish guidance for FY25 with target revenue growth of 35-40% (20% organic vs 8-10% IPM growth, plus INR 1,000 Cr+ via acquisitions). Management also guided for an additional 100 bps EBITDA margin expansion in FY25 driven by operating leverage and mix shift.

Rationale

  • Delivered a full-year turnaround to profitability with FY24 PAT of INR 40 Cr compared to a loss of INR 11 Cr in FY23, driven by a 75% YoY increase in EBITDA.
  • Significant revenue outperformance relative to the industry, growing 19% YoY in FY24 (reaching INR 3,922 Cr) against an Indian Pharmaceutical Market (IPM) growth rate of 7.6%.
Q1 FY2025
8.5

Management confirmed FY25 revenue growth guidance of 35%+; organic growth is trending at 16% (2x market) with the remainder driven by inorganic integration scheduled for Q2 and Q3.

Rationale

  • Delivered 22% YoY revenue growth (₹1,097 Cr), significantly outperforming the Indian Pharmaceutical Market (IPM) growth rate of 9% for the same period.
  • PAT surged 219% YoY to ₹21 Cr, driven by operational EBITDA growth and a massive reduction in net finance costs following the ₹1,000 Cr IPO capital infusion.
Q2 FY2025
8.0

Management maintained guidance for organic growth at 1.5x-2x the market rate. They are on track to achieve ₹1,000 Cr+ in annualized revenue from acquisitions in FY25 (₹750 Cr completed, ~₹60 Cr in MoUs signed). Full financial impact of Q2 acquisitions will reflect from Q3 FY25.

Rationale

  • Delivered robust revenue growth of 31% YoY (₹1,301 Cr), significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 8%. Organic growth remained strong at 15% (nearly 2x market).
  • Operational efficiency is improving with EBITDA margins expanding 40 bps YoY to 3.3% and EBITDA growing 49% YoY, driven by procurement efficiencies and a higher-margin product mix from acquisitions.
Q3 FY2025
7.8

Management maintained guidance to grow organic business at 1.5x-2x IPM growth; targeted INR 1,000 Cr of inorganic revenue for FY25 (INR 800 Cr achieved); specifically guided for Operating Cash Flow (OCF) to turn positive in FY26.

Rationale

  • Revenue grew 37% YoY to INR 1,359 crores, with organic growth of 17% significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 7%.
  • Strong margin expansion across the board: Gross margins improved 73 bps YoY to 9.8%, while EBITDA margins expanded 80 bps YoY to 3.7%, driven by procurement efficiencies and a shift toward high-margin medical devices and specialty pharma.
Q4 FY2025
8.2

Strongly positive: FY26 revenue growth targeted at >30% (consistent with FY25), full-year EBITDA margins guided to exceed 4.0%, and 6 strategic acquisitions already in pipeline to expand geographical and product reach.

Rationale

  • Delivered robust FY25 revenue growth of 30% YoY (₹5,096 Cr), significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 8%; organic growth of 16% remains 2x the industry average.
  • Successfully transitioned to operating cash flow (OCF) positive in H2 FY25 (~₹50 Cr) with a clear roadmap for full-year OCF positivity in FY26 driven by a 5% planned reduction in working capital days.
Q1 FY2026
7.8

Maintained FY26 guidance of 30% revenue growth (organic + inorganic) and full-year EBITDA margins of 4%+. Management expects to be Operating Cash Flow positive for the full year.

Rationale

  • Revenue grew 28% YoY (31% on a like-for-like basis) to ₹1,404 Cr, significantly outperforming the Indian Pharma Market (IPM) growth of 9%, supported by a healthy 15% organic growth rate.
  • Gross margins expanded 83 bps YoY to 9.9% and EBITDA margins expanded 82 bps YoY to 3.6%, driven by a shift toward margin-accretive categories like medical devices and diagnostics alongside procurement efficiencies.
Q2 FY2026
8.8

Maintained FY26 revenue growth guidance of ~30% (requires ~31-35% in H2); guided for strong positive OCF of INR 100cr+ for FY26 and NWC reduction to 60 days by year-end.

Rationale

  • Strong financial performance with revenue up 20.8% YoY (23.4% on LFL basis) and organic growth of 13.4%, significantly outperforming Indian Pharmaceutical Market (IPM) growth of 7.3%.
  • Material margin expansion with EBITDA growing 46% YoY and margins reaching 4.0% (up 69 bps YoY); strategic pivot to MedTech segment (60% of new M&A) is expected to add 50-75 bps to EBITDA margins proforma.
Q3 FY2026Latest
7.5

Management maintained full-year FY26 guidance for Operating Cash Flow of INR100 crores and EBITDA margins north of 4%. This implies a significantly strong Q4 performance, including achieving >INR100 crores OCF and >4.5% EBITDA margin, alongside 35% revenue growth to meet the 30% like-to-like full-year target. Annualized MedTech revenue is guided to cross INR1,000 crores post-integration, with a pro forma positive impact of 70-90 bps on gross margin and 50-75 bps on EBITDA margin.

Quarter summary

  • Achieved significant organic growth and expanded market share, outperforming the industry in Q3 FY26.
  • Made strategic acquisitions in the high-margin MedTech segment, positioning for future growth and margin enhancement.

Rationale

  • The company delivered strong revenue growth, with Q3 FY26 revenue up 26% YoY to INR1,707 crores and organic growth at a high 17.1% YoY, outpacing the industry's 12% growth and indicating market share gains.
  • Gross profit, EBITDA, and adjusted PAT all showed healthy YoY growth (29%, 36%, 36% respectively) with margin expansion (GP margin +30 bps YoY to 10.1%, EBITDA margin +30 bps YoY to 4%).

Future Growth Prospects

Growth score: 8.8Visibility: 85%Updated: 24 Feb 2026, 01:42 am

Catalysts (next 12-24 months)

Total triggers: 3Visible per view: 1 / 2 / 3Slides: 3

Swipe or use arrows to browse all triggers.

mnanext 6-12 monthsImpact: marginQty: 75 bps

MedTech Segment Integration and Scale

Timeline

  • in progressQ2 FY26 · concall

    Closed five acquisitions during July to October 2025; proforma revenue of INR 545 Cr.

  • scaledQ3 FY26 · concall

    Closed Anand Medilink, Ace Cardiopathy, Bioaide Technologies; segment proforma revenue now >INR 1,000 Cr.

    Added scale in IVD, Cardiology, POCT devices.

Show full timeline (3)
  • commissionedFeb-2026 · ppt

    Acquisition of Anand Chemiceutics closed on Feb 07, 2026.

    Final deal of the announced 7 M&A transactions closed.

Supporting evidence

• Q3/FY26 · concall · Post-integration, annualized revenue will cross over INR 1,000 crores in MedTech segment with 50 to 75 bps positive impact on EBITDA margin.

otherFY26EImpact: fcfQty: 60 units

Working Capital Optimization to 60 Days

Timeline

  • unknownFY25 · ar

    Net Operating Working Capital Days stood at 70 days.

  • in progressQ1 FY26 · ppt

    NWC days at 66.

    Reduction through ERP-driven controls.

Show full timeline (3)
  • scaledQ3 FY26 · ppt

    NWC days at 61 on like-for-like basis. On track for 60-day target.

    Reflects 2 days inventory and 1 day receivable reduction.

Supporting evidence

• Q3/FY26 · concall · Net working capital days on a like-to-like basis improved to 61 days in Q3 FY26 from 66 in Q1.

otherFY26EImpact: marginQty: 20 bps

Manpower Operating Leverage

Timeline

  • announcedQ1 FY26 · concall

    Annual salary hikes implemented; impacted margins by 20 bps.

    Operating costs increased 9% QoQ vs 5% revenue growth.

  • scaledQ3 FY26 · concall

    Expenses were 6.4% in Q1, now gone down to 6.1%.

    Revenue growth catching up to fixed costs.

Supporting evidence

• Q1/FY26 · concall · Fixed manpower costs have been fully baked in... positive impact of operating leverage will start playing out.

Variant perception

Non-consensus view
Consensus

Market may underappreciate the margin expansion potential of the MedTech segment, which carries double-digit EBITDA vs. the consolidated 4%.

Upside
  • ENTERO holds ~10% market share in high-growth GLP-1 drugs launched by Eli Lilly in India.
Show more (1)
  • 70-90 bps gross margin improvement purely from pro-forma MedTech integration is likely conservative.
Downside
  • Interest costs are rising sharply (INR 11.5 Cr in Q3) as IPO cash is deployed for M&A.
Show more (1)
  • Requirement for 35% growth in Q4 FY26 to meet full-year guidance leaves little room for error.
base case80% conf
Growth: 30

Quick takeaway

17% organic growth persistence plus full-year impact of 7 FY26 acquisitions

Risk watch: Integration delays of the 7 newly acquired companies

Show details (2 drivers, 2 risks)

Drivers

  • 17% organic growth persistence plus full-year impact of 7 FY26 acquisitions
  • Consolidated EBITDA margins reaching 4.0% by end of FY26

Risks

  • Integration delays of the 7 newly acquired companies
  • Higher interest costs due to cash usage for M&A
upside case60% conf
Growth: 35

Quick takeaway

MedTech proforma contribution exceeding INR 1,000 Cr annualized earlier than expected

Risk watch: Aggressive competition from other organized aggregators

Show details (2 drivers, 2 risks)

Drivers

  • MedTech proforma contribution exceeding INR 1,000 Cr annualized earlier than expected
  • EBITDA margins reaching 4.5% to 4.75% pro forma

Risks

  • Aggressive competition from other organized aggregators
  • Regulatory shifts in drug margin structures
downside case50% conf
Growth: 24

Quick takeaway

Slowdown in organic growth to IPM levels (12%)

Risk watch: Macroeconomic slowdown impacting consumption

Show details (2 drivers, 2 risks)

Drivers

  • Slowdown in organic growth to IPM levels (12%)
  • Working capital stuck at 66+ days

Risks

  • Macroeconomic slowdown impacting consumption
  • High attrition in key sales and integration teams

Story of the Stock - Top Strategies

Latest Fiscal Years: FY26, FY25Top strategies (ranks 1-3) per year
Curated from latest transcripts
Fiscal YearFY26
#1Impact: HIGH

Aggressive Inorganic Expansion in MedTech Segment

On track to close INR 1,000 Cr+ revenue acquisitions with +50-75 bps EBITDA margin expansion

Closing 7 deals through FY26; 5 closed between July and October 2025
Show more

The company is executing 7 M&A transactions focused on the high-margin MedTech space to cross INR 1,000 Cr in segment revenue and enhance the overall margin profile.

Impact: 1000 Cr

Evidence

On track to close INR1,000 crores plus revenue acquisitions through 7 M&A transactions
Estimated positive impact of 70 to 90 basis points on gross margin and 50 to 75 bps on EBITDA margin
Around 60% of our M&A is happening in the MedTech segment
#2Impact: HIGH

Organic Market Share Capture and IPM Outperformance

Consistently outperforming the Indian Pharmaceutical Market (IPM) growth by 1.6x to 1.8x

Ongoing; achieved 13.4% organic growth in Q2 FY26 vs 7.3% IPM growth
Show more

Entero leverages its pan-India distribution network of 113 warehouses to grow its organic revenue significantly faster than the broader industry rate.

Impact: 1.8 x

Evidence

Organic growth was 13.4% year-on-year, which is approximately 1.8x the IPM growth rate
Continue to deliver around 1.6 times the market growth rate
Revenue grew by 20.8% year-on-year and 11.9% quarter-on-quarter to INR1,571 crores
#3Impact: HIGH

Working Capital Optimization and Cash Flow Generation

Targeting 60 NWC days to generate INR 100 Cr+ in positive operating cash flow

Targeting 60 days by end of FY26; improved from 69 days to 63 days in Q2 FY26
Show more

The company is utilizing proprietary ERP systems and data-driven inventory planning to reduce net working capital days and improve liquidity for future acquisitions.

Impact: 100 Cr

Evidence

Confident of closing FY26 with working capital days of around 60
Delivering strong positive operating cash flow for the year in the range of INR100 crores plus
Net working capital days has improved from about 69 days a year ago to 63 days in Q2 FY26
Fiscal YearFY25
#1Impact: HIGH

Disciplined Inorganic Growth (M&A)

₹792 Cr annualized revenue contribution from 10 strategic acquisitions in FY25

10 acquisitions integrated in FY25; 6 new acquisitions announced for FY26
Show more

Entero aggressively consolidates the fragmented healthcare distribution market by acquiring high-quality regional players that add new geographies, product segments, or specialized capabilities.

Impact: 792 Cr

Evidence

Successfully completed and integrated 10 strategic acquisitions during the year, contributing Rs. 792 crores in annualized revenue.
Acquisitions are EBITDA margin accretive on a blended level and targeted to add 'either new geography, new product segment or capabilities.'
Announced six new strategic acquisitions for FY26 expected to add over Rs. 400 crores of annualized revenues.
#2Impact: HIGH

Organic Scale-up in Underserved Markets

16% organic growth in FY25, outperforming industry (IPM) growth by 2x

Continuous scaling; reached 500 districts and 95,300+ pharmacies by end of FY25
Show more

The company focuses on deepening market penetration in Tier 2 and Tier 3 cities, increasing wallet share with existing pharmacies and hospitals through a technology-led supply chain.

Impact: 16 %

Evidence

Registered 16% organic growth against an IPM growth of 8%, thereby outpacing the industry growth by 2x.
Presence now spans 500 districts across 20 states supported by 101 warehouses.
Customer base surpassed 100,000 across pharmacies and hospitals in FY25.
#3Impact: HIGH

High-Margin Product Mix Diversification

57 bps gross margin expansion to 9.5% via specialty segments

Ongoing; contributed to margin expansion throughout FY25
Show more

Entero is shifting its product portfolio toward margin-accretive categories such as medical devices, surgical consumables, and specialty pharmaceuticals that offer higher returns than standard generics.

Impact: 57 bps

Evidence

Gross margins improved by 57 basis points to 9.5% aided by margin accretive categories and procurement efficiencies.
Product portfolio expanded to include 'medical devices, diagnostic consumables and equipments, surgical consumables and specialty pharma.'
Non-medicine portfolio (surgical, equipment, etc.) reached approximately 10% of total revenues by mid-FY25.

Business Segments

Community

Share your view anonymously. Comments are public and sorted newest first.

Anonymous post · 1500 characters left

Loading comments...